Research programme: factor XIIa inhibitors - X-37
Latest Information Update: 28 Dec 2023
At a glance
- Originator X-37
- Class Anticoagulants; Small molecules
- Mechanism of Action Factor XIIa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Blood coagulation disorders
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for research development in Blood-coagulation-disorders in USA
- 14 Nov 2019 Factor XIIa inhibitors - X-37 is available for licensing as of 27 Nov 2019. https://x37.ai/
- 14 Nov 2019 Early research in Blood coagulation disorders in USA (unspecified route) before November 2019